Tau PET imaging can identify Alzheimer's subtype associated with psychosis: Study

Tau positron emission tomography (PET) neuroimaging gives the opportunity to evaluate tau pathology in-vivo, so that clinical symptomatology can be compared with disease pathology. [18F]-AV1451 (Flortaucipir) is a PET ligand having high affinity for insoluble aired-helical filaments (PHFs) of hyperphosphorylated tau. 

Against the above background, J. J. Gomar, Feinstein Institutes for Medical Research, Manhassett, NY, USA, and colleagues aimed to determine whether the development of psychosis and worsened prognosis in AD is associated with an increased burden of tau pathology that can be identified with tau imaging. 

For this purpose, the researchers identified subjects within the Alzheimer's disease neuroimaging initiative (ADNI) who had [18F]-AV1451 imaging at baseline and became psychotic over the course of the study (N = 17). They were then matched in the ratio of 1:3 for gender, age, and education to subjects who had [18F]-AV1451 imaging at baseline and did not become psychotic (N = 50). Baseline [18F]-AV1451 retention was then compared along with cognitive and functional baseline and longitudinal change, in those who became psychotic over the course of participation in ADNI with those who did not. 

The authors conclude, "the results suggest that increases in tau pathology in frontal, medial temporal, and occipital cortices, visualized with [18F]-AV1451 binding, are associated with psychosis and a more rapid cognitive and functional decline."

Reference:

Gomar, J.J., Tan, G., Halpern, J. et al. Increased retention of tau PET ligand [18F]-AV1451 in Alzheimer's Disease Psychosis. Transl Psychiatry 12, 82 (2022). https://doi.org/10.1038/s41398-022-01850-z